CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • The Arrival of Personalized Immunotherapy?

    A new paper from a CRI scientist makes a strong case f or the value of truly…

    October 10, 2014| Matthew Tontonoz
  • Uncovering Cancer Targets

    The CRI Young Philanthropist Fellow's research on gene expression in cancer could impact the way lymphoma is…

    September 17, 2014| CRI Staff
  • AACR Report Highlights Cancer Immunotherapy

    The AACR Cancer Progress Report provides a "state-of-the-union" look at where we are in cancer research.

    September 17, 2014| Alexandra Mulvey
  • Coast to Coast for a Cure

    Cyclist Joel Paula biked 4,000 miles to raise money for the Cancer Research Institute, and to prove…

    September 9, 2014| CRI Staff
  • FDA Approves New Cancer Immunotherapy

    Merck's new immunotherapy, Keytruda (pembrolizumab), was approved today by the FDA, making it the first PD-1 inhibitor…

    September 4, 2014| Jill O'Donnell-Tormey, PhD
  • CRI Names Winners of Top Scientific Prize

    Four scientists to be honored with the 2014 Coley Award for their contributions to the discovery of…

    September 3, 2014| Matthew Tontonoz
  • A Pilgrimage in Spain to Fight All Cancers

    Having had four brothers battle cancer, David was inspired to make a 800km fundraising trek a journey…

    August 19, 2014| CRI Staff
  • When AIDS Was a Cancer

    Before AIDS was recognized as an immune disorder, it was seen as a cancer. Find out what…

    August 8, 2014| Matthew Tontonoz
  • Two Immunotherapies Clear Important Regulatory Hurdles

    The anti-PD-1 drug nivolumab receives the go-ahead for use in Japan, while in the U.S., CAR-T cells…

    July 8, 2014| Matthew Tontonoz
Previous Page
1 … 86 87 88 89 90 91
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute